Agios Pharm (AGIO)

Nov 5, 2026

Agios Pharmaceuticals is reducing its research and development workforce by over 100 roles, representing more than a 35% cut. The Cambridge-based company is making this strategic shift to prioritize commercial launches and aims to achieve profitability by 2028. Agios is a commercial-stage company that develops medicines for patients with rare diseases.

Nov 5, 2026

Agios Pharmaceuticals reported record third-quarter product revenue of $55.4 million, a four-fold increase from the prior year, primarily driven by the U.S. launch of mitapivat in thalassemia. The company is preparing for the potential launch of mitapivat in sickle cell disease, with an FDA decision expected by February 2027, despite a recent request for additional safety data. Agios aims for non-GAAP profitability by 2028, supported by significant R&D headcount reductions and $907 million in cash reserves, while advancing its rare hematology pipeline.

Nov 5, 2026

AGIOS PHARMACEUTICALS ($AGIO) reported its Q3 2026 earnings, beating analyst estimates for both earnings per share and revenue. The company reported an EPS of -$1.09 against an estimated -$1.25, and revenue of $55.39 million against an estimated $54.27 million. The article also provides details on insider trading activity, hedge fund movements, congressional stock trading, and recent analyst price targets for AGIO.

Nov 2, 2026

The US FDA has extended its review deadline for Agios Pharmaceuticals' mitapivat, an oral pyruvate kinase activator for sickle cell disease, from November 1, 2026, to February 1, 2027. This three-month extension allows the agency to evaluate additional safety information submitted by Agios, classified as a major amendment, to determine if a Risk Evaluation and Mitigation Strategy (REMS) is required. Despite a boxed warning for liver injury with mitapivat in thalassemia, Agios asserts no similar severe liver injury has been reported in sickle cell patients, maintaining its positive benefit-risk assessment.